EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD

Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar-Zadeh, Keiichi Sumida, Csaba P. Kovesdy

Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1914-1927

DOI: 10.2215/cjn.0000001188 ↗
AbstractBibliografische Angaben

Abstract

Key Points In this large cohort of US veterans with CKD, unlike niacin, long-term fibrate use (compared with statin use) was associated with slower eGFR decline. There was no statistically significant difference in the risk of major adverse kidney events in fibrate and niacin users compared with statin users. The potential renoprotective effects of fibrates can be particularly useful in patients with CKD who require triglyceride-lowering and HDL-elevating effects. Background Dyslipidemia, distinctly characterized by hypertriglyceridemia and impaired HDL cholesterol metabolism in patients with CKD, is associated with kidney disease progression. However, evidence on the renal outcomes of triglyceride-targeting lipid-lowering therapies, such as fibrates and niacin, often prescribed to patients with non–dialysis-dependent CKD, is insufficient and equivocal. Methods We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US veterans to identify patients with incident CKD initiating de novo lipid-lowering therapies. We compared eGFR decline from baseline and the odds of rapid eGFR decline in fibrate and niacin initiators versus statin initiators using the mixed-effects model–predicted 1-, 3-, and 10-year eGFR slopes, adjusted for baseline covariates. We also compared the risk of major adverse kidney events (composite of a sustained ≥57% decrease in eGFR from baseline, sustained eGFR

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →